ProCE Banner Activity

EPCORE NHL-1 Update: Pivotal Phase I/II Trial of Epcoritamab in Patients With R/R B-Cell NHL

Conference Coverage
Slideset

In this updated analysis in patients with R/R B-cell NHL, epcoritamab monotherapy demonstrated deep and durable responses and favorable long-term outcomes with no new safety signals.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis